NCT02374931

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Vanderbilt-Ingram Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.

Detailed description

PRIMARY OBJECTIVES: I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC). OUTLINE: Patients undergo 18F-FES PET/CT imaging over 30 minutes. After completion of study, patients are followed up for 30 days.

Conditions

• Deep Fibromatosis/Desmoid Tumor
• Familial Adenomatous Polyposis

Interventions

Type	Name	Description
DRUG	F-18 16 Alpha-Fluoroestradiol	Undergo 18F-FES PET/CT
PROCEDURE	Positron Emission Tomography	Undergo 18F-FES PET/CT
PROCEDURE	Computed Tomography	Undergo 18F-FES PET/CT
OTHER	Laboratory Biomarker Analysis	Correlative studies

Timeline

• Start date: 2015-04-01
• Primary completion: 2017-07-01
• Completion: 2017-12-01
• First posted: 2015-03-02
• Last updated: 2019-10-03

Locations

1 site across 1 country: United States